Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Risk of Cancer Among Sarcoidosis Patients With Biopsy-verified Nonnecrotizing Granulomatous Inflammation: Population-based Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Is Real-world Evidence Really Real?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis: Results From the SPARTAKUS Cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Socioeconomic functioning in patients with brain abscess - a nationwide, population-based cohort study in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Tuberculosis incidence and mortality in people living with human immunodeficiency virus: A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To assess the long-term risk of hematologic cancers, invasive solid tumors, and nonmelanoma skin cancer (NMSC) among sarcoidosis patients with biopsy-verified nonnecrotizing granulomatous inflammation.

METHODS: We used Danish administrative registers with nationwide coverage to construct a cohort of 3892 patients with sarcoidosis and an age- and sex-matched comparison cohort of 38,920 population controls. For all patients, a biopsy demonstrating nonnecrotizing granulomatous inflammation had been obtained from the lower respiratory tract at the time of diagnosis. Study outcome was time to diagnosis of cancer. Follow-up began at time of sarcoidosis diagnosis and continued for up to 10 years. We calculated hazard ratios (HRs) as estimates of the cancer risk among the patients with sarcoidosis relative to that among the population controls and used cumulative incidence functions to calculate absolute 10-year risk estimates.

RESULTS: We observed an increased long-term risk of hematologic cancers (HR during the first 2 years of follow-up: 2.71 [95% CI 1.18-6.25]; HR after > 2 years of follow-up: 2.12 [95% CI 1.29-3.47]) and NMSC (HR after > 2 years of follow-up: 1.82 [95% CI 1.43-2.32]) among the patients with sarcoidosis. An increased risk of invasive solid tumors was only observed during the first 2 years (HR 1.55, 95% CI 1.18-2.04). Compared with the population controls, the patients with sarcoidosis had an increased absolute 10-year risk of hematologic cancers (risk difference 0.56%, 95% CI 0.11-1.01%) and NMSC (risk difference 1.58%, 95% CI 0.70-2.47%).

CONCLUSION: Sarcoidosis patients with biopsy-verified nonnecrotizing granulomatous inflammation have an increased long-term risk of hematologic cancers and NMSC compared with the general population.

Original languageEnglish
JournalJournal of Rheumatology
Volume49
Issue number2
Pages (from-to)186-191
Number of pages6
ISSN0315-162X
DOIs
Publication statusPublished - Feb 2022

Bibliographical note

© 2022 by the Journal of Rheumatology.

ID: 74079962